Mardia Samyoung Capillary Tubes Company Ltd has launched its functional website at www.mardiasygltd.com , marking a key compliance step following its acquisition as a going concern. The company notified the BSE on August 19, 2026, confirming that the digital platform is now live to facilitate the dissemination of information and disclosures required under market regulations.

The establishment of the website is part of the company's post-acquisition restructuring efforts. Management stated that the site has been developed specifically to meet the disclosure obligations mandated by Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Compliance and Updates

The company is currently in the process of populating the website with requisite information and disclosures applicable following the acquisition. Mardia Samyoung assured stakeholders that it will ensure timely updates to the platform in accordance with the applicable provisions of the SEBI LODR Regulations.

This intimation was submitted to the stock exchange for information and records by Dhaval Dharmendrabhai Joshi, Managing Director of the company.

Mardia Samyoung Capillary Tubes Company Limited reported a standalone net profit of ₹105.06 lakh for the quarter ended June 30, 2026 (Q1FY27), marking an 8.4% decline from the ₹114.72 lakh profit recorded in the preceding quarter ended March 31, 2026. Revenue from operations fell sharply to ₹2,483.91 lakh from ₹6,111.74 lakh in Q4FY26. The results were approved by the Board of Directors at a meeting held on August 11, 2026, in Ahmedabad. The decline in profitability comes against a backdrop of significant governance concerns highlighted by statutory auditors regarding inventory verification and fund utilization.

The company’s statutory auditors, S.K. Bhavsar & Co., Chartered Accountants, issued a limited review report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, containing multiple "Emphasis of Matter" paragraphs. The auditors stated they could not verify the physical stock or inventory as of June 30, 2026, as management failed to furnish a representation letter confirming its existence and condition. Consequently, the auditors could not comment on the valuation of inventory reflected in the financial statements.

Further material disclosures revealed significant gaps in transaction verification. The auditors noted that sales and purchase invoices necessary to verify transactions and the end-utilization of funds raised during the quarter were not made available for full verification. During the period, the company converted 1,17,15,000 warrants into equity shares, raising ₹15.82 crore (₹15,81,52,500) comprising face value and a share premium of ₹13.50 per share. Despite verifying the receipt of these funds, the auditors could not confirm their utilization for stated purposes due to missing documentation.

A critical concern involves interest-free advances aggregating ₹22.84 crore given by the company during the quarter. Supporting documentation for these advances was not provided, leaving the auditors unable to assess their recoverability or business rationale. Additionally, confirmations for certain trade receivable and payable balances were not obtained, and adequate alternative procedures could not be performed, limiting assurance on the accuracy of these balances.

Financial Performance Summary

The company also announced the shifting of its corporate office from Gandhinagar to Ahmedabad, effective August 11, 2026. The new address is Office No. A-404, Titanium Square, S.G. Highway, Thaltej, Ahmedabad. The Board meeting commenced at 08:00 PM and concluded at 09:00 PM on August 11, 2026.

What the Numbers Show

The divergence between the substantial capital infusion of ₹15.82 crore via warrant conversion and the simultaneous extension of ₹22.84 crore in interest-free advances raises questions about capital allocation efficiency. With revenue dropping over 59% quarter-on-quarter and auditors unable to verify inventory or trade balances, the financial statements present limited transparency into operational health. The absence of cost of materials consumed (reported as ₹0.00) alongside significant purchases of stock-in-trade (₹2,554.43 lakh) suggests potential classification nuances or reporting gaps that require further clarification from management.